ADS Biosystems Inc. focuses on novel approaches against infectious diseases, cancer and metabolic diseases. We have established state-of-art platforms for early cancer detection with new cancer markers. ADS has produced and commercialized quantitative ELISA kit for RBD binding antibodies against RBD domain of SARS-CoV-2, luciferase and GFP fusion proteins of RBD and Nucleocapsid (N) for rapid detection. All these SARS-CoV-2 products have been verified with recovered COVID-19 patients, vaccinated subjects and healthy controls. We have also developed a rabbit antibody against the RBD domain, which works both for Western blot analysis and ELISA.
We are looking forward to collaborating with you for the fight against COVID-19, cancer, and metabolic diseases.